Data from clinical studies have drawn attention that anti-TNF-α (infliximab) antibody shows efficacies as a rescue therapy in some patients with AIH, but displays high risks of severe adverse events, especially infections (10, 11). The gene discussed is TNF; the disease is autoimmune hepatitis.